TCTR20191217006Unknown1 期
Multicenter, open-label, single arm study of combination therapy of surgery, antifungal agents and antibacterial agents for human pythiosis
็Health Systems Research Institute0 个研究点目标入组 50 人开始时间: 2019年12月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 100 Years（—）
- 性别
- All
入选标准
- •1.Patient age of 18 years or above
- •2.Patient is diagnosed with human pythiosis based on clinical presentation and additional 2 out of 4 criteria below;
- •-Patient has positive serum P. insidiosum antibody based on in-house enzyme-linked immunosorbent assay (ELISA)
- •-Positive cultures for P. insidiosum, confirmed by zoospore induction and nucleic acid sequencing, from tissue samples
- •-Consistent pathological finding with broad-sized hyaline septate hyphae in tissues
- •-Detection P. insidiosum DNA by polymerase chain reaction (PCR) in tissue samples
排除标准
- •1.Patient has other concurrent fungal infection
- •2.Patient is not willing to follow up according to the study protocol
研究者
相似试验
进行中（未招募）
1 期
A multicenter prospective study on the cost / benefit / safety of Sofosbuvir administered to patients with chronic hepatitis C virus and Mixed CryoglobulinemiaHCV chronic hepatitis and Mixed CryoglobulinemiaMedDRA version: 17.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: LLTClassification code 10027756Term: Mixed cryoglobulinemiaSystem Organ Class: 100000004866EUCTR2014-004134-26-ITCentro Masve -Università degli Studi di Firenze-AOUC30
进行中（未招募）
1 期
An open label study to provide extended treatment in patients treated with Talazoparib.Advanced solid tumorsEUCTR2016-001972-31-DEPfizer, Inc.150
进行中（未招募）
1 期
An open label study to provide extended treatment in patients treated with Talazoparib.EUCTR2016-001972-31-GBPfizer, Inc.150
进行中（未招募）
1 期
An open label study to provide extended treatment in patients treated with Talazoparib.Advanced solid tumorsEUCTR2016-001972-31-PLPfizer Inc.150
进行中（未招募）
1 期
An open label study to provide extended treatment in patients treated with Talazoparib.EUCTR2016-001972-31-HUMedivation, Inc.150